(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera seeks to raise up to $292.2 million in US IPO Venture capital firm ARCH Ventures founded Metsera in 2022 Jan 27 (Reuters) - Metsera, which is developing weight-loss drugs, said on Monday ...

By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to ...